Peptide.Express Research Team||
Is Retatrutide FDA Approved? Current Status, Clinical Trials & Research Use
No. Retatrutide is not FDA approved. FDA says it is not a component of an approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. Registered trials and a sponsor’s plan to file an application are not approval. Peptide.Express supplies research material only. This page is not a treatment guide and not a way to obtain a medicine.
FDA status
On the page FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, checked 6 October 2026 and read again on 7 October 2026, FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, that they are not components of FDA-approved drugs, and that they have not been found safe and effective for any condition. The same page says FDA has warned companies that sold unapproved drugs containing retatrutide, including products labeled “for research purposes” or “not for human consumption” and sold to consumers for human use with dosing instructions.
That is a statement about legal status and about marketing the agency has already objected to. It is not a finding that every laboratory chemical with this name has been seized, and it is not personal legal advice.
What the name refers to
Retatrutide is the international nonproprietary name for the investigational peptide Eli Lilly developed as LY3437943, a single 39-residue fatty-acylated backbone studied at the GLP-1, GIP, and glucagon receptors. Identity figures used on the compound guide — CAS 2381089-83-2, formula C221H342N46O68, average mass 4,731 Da — come from the IUPHAR/BPS Guide to Pharmacology ligand 13769 and PubChem CID 171390338, not from an approved-drug label. The retatrutide compound guide keeps those identity records and the mechanism discussion.
Trial status is not approval
ClinicalTrials.gov records, read 7 October 2026, are the status source for the three trials below. A registry status can change. This page does not claim that any trial is enrolling, and it does not treat completion as approval.
| Record | Population named on the record | Status read on 7 Oct 2026 |
|---|---|---|
| TRIUMPH-1 NCT05929066 | Adults with obesity or overweight, without type 2 diabetes, including knee osteoarthritis and obstructive sleep apnea subsets | Completed |
| TRIUMPH-2 NCT05929079 | Adults with type 2 diabetes and obesity or overweight | Completed |
| TRIUMPH-3 NCT05882045 | Adults with obesity and established cardiovascular disease | Completed |
On 23 July 2026 Eli Lilly said it planned to submit a biologics license application for retatrutide in the first quarter of 2027. The release was read again on 7 October 2026. That sentence is the sponsor’s stated filing plan. It is not an FDA approval date and not a launch date. A planned submission can move, and an application can be refused or delayed.
Prescribing and investigational access
Ordinary prescribing is for an approved drug product, under its labeling. Retatrutide has no approved drug product to prescribe. Authorized research access, where it exists, is a separate arrangement between a sponsor, investigators, and regulators. This page does not describe every possible investigational mechanism, and it does not say that buying research material is one of them.
Compounding
The FDA page linked above states that retatrutide cannot be used in compounding under federal law and that it is not a component of an FDA-approved drug. A 9 September 2025 warning letter to GLP-1 Solution states the eligibility point in more detail: compounded retatrutide products did not qualify for the 503A exemptions because retatrutide is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list, and did not qualify for the 503B exemptions because retatrutide does not appear on the 503B bulks list and is not used to compound a drug that appears on the drug shortage list. Those are the agency’s stated reasons. They are not a complete account of every future listing decision.
What a research-use label does not do
“Research use only” and “not for human consumption” are labels. They are not an FDA authorization, not an exemption from the new-drug rules, and not evidence that a product is lawful for a particular buyer or use. FDA has already warned sellers who used those words while offering retatrutide to consumers for human use. A label does not convert research material into an approved drug, and it does not make a certificate of analysis into a license to administer the material.
Research material is not an approved drug product
An approved drug product is a specific manufactured article with an approved application, pharmaceutical manufacturing controls, and approved labeling. Research-grade retatrutide offered for laboratory work is not that article. It is not the investigational product Lilly supplies to its trials. Analytical documents, where they exist, describe the lot they name. They do not confer approval.
Peptide.Express scope
Peptide.Express sells material for in-vitro laboratory research. Not for human or veterinary use. The catalog is not a route to personal treatment, and this page does not invite that use. How a certificate is read is on the quality methodology page. Published certificates are in the certificate library. The retatrutide safety data sheet is the hazard document. The research listing is the storefront record for the material this site sells. It is not a prescription offer.
Questions
- Is retatrutide FDA approved?
- No. As of 6 October 2026, retatrutide is not an FDA-approved drug. FDA states that it is not a component of an approved drug and has not been found safe and effective for any condition.
- Can retatrutide be compounded?
- FDA states that retatrutide cannot be used in compounding under federal law. A research-use label does not change that position and is not an authorization to compound or to dispense the substance as a drug.
- Does a completed trial mean retatrutide is approved?
- No. Trial completion, a sponsor press release, and a plan to submit an application are not approval. Approval is an FDA decision on an application for a specific drug product.
Sources checked 6 October 2026
- FDA. Concerns with unapproved GLP-1 drugs used for weight loss. Supports the not-approved, not-a-component, and cannot-be-compounded claims, and the warning about research-labeled products sold for human use.
- FDA warning letter to GLP-1 Solution, 9 September 2025. Supports the 503A and 503B eligibility statement in the compounding section.
- ClinicalTrials.gov NCT05929066, NCT05929079, and NCT05882045. Support only the trial statuses in the table.
- Eli Lilly, 23 July 2026. Supports the sponsor’s statement that it planned a first-quarter 2027 submission. It does not support an approval or launch date.
- IUPHAR/BPS ligand 13769 and PubChem CID 171390338. Identity only. Not regulatory status.
Attribution and corrections
Written by the Peptide.Express Research Team. No separate regulatory reviewer is named, because none is on record for this page. The chemist who reviews compound identity records does not review this regulatory note, and this page does not attribute it to him. To report a correction, use the contact form or [email protected]. The FDA pages were checked on 6 October 2026 and read again on 7 October 2026; the quoted position was unchanged. ClinicalTrials.gov was read on 7 October 2026. NCT05882045 overall status is Completed, and that registry record was last posted on 30 July 2026. Re-check FDA and ClinicalTrials.gov before relying on a status that may have moved.